



Fluoroless Left Atrial Access for Radiofrequency and Cryoballoon Ablations using a Novel Radiofrequency Transseptal Wire

HIGHLIGHTS

- ▶ The **VersaCross™ RF Transseptal Solution** can enable fluoroless transseptal puncture in ablation procedures.
- ▶ Efficient procedure with average transseptal puncture time under 20 minutes.
- ▶ Zero exchanges required for transseptal puncture.

INTRODUCTION

- ▶ Procedure efficiency and transseptal puncture (TSP) remain a barrier to the full adoption of fluoroless procedures to reduce radiation exposure and associated health risks.
- ▶ This study reports the first clinical experience using the **VersaCross™ RF Transseptal Solution** (Baylis Medical*) for more efficient left atrial (LA) access through reduced device exchanges to facilitate fluoroless radiofrequency ablation (RFA) and cryoballoon ablation (CBA).

METHODS

- ▶ Fluoroless RFA and CBA procedures at two centers were retrospectively evaluated for procedural efficiency and safety.
- ▶ The **VersaCross™ RF Transseptal Solution**, consisting of a transseptal sheath, shapeable dilator, and RF wire (J-tip or pigtail), was used to cannulate the superior vena cava (SVC), perform RF TSP, and deliver RF ablation or the FlexCath Advance™ Steerable Sheath (Medtronic) in CBA.
- ▶ The **VersaCross™ RF Transseptal Solution** was visualized without fluoroscopy using:
 - A. Electroanatomic mapping (EAM) using the **DuoMode™ Cable** (Baylis Medical) and EnSite Precision™ Cardiac Mapping System (Abbott), and intracardiac echocardiography (ICE).
 - B. ICE only.
- ▶ RFA or CBA procedures were then performed as per usual protocol.

RESULTS

- ▶ 126 patients underwent RFA (n=72) or CBA (n=54) for left-sided cardiac arrhythmias.
- ▶ Fluoroless TSP was successful in 100% of cases regardless of septal anatomy. Device exchanges were not required for TSP or repositioning on the septum.
- ▶ All procedures were 100% successful without any intraprocedural complications.
- ▶ Average procedure time was 104.4 ± 38.0 min for RFA and 91.1 ± 22.1 min for CBA.

- ▶ Transseptal Puncture Time (Figure 1)
 - 2.8 ± 1.0 min for RFA and 3.5 ± 1.6 min for CBA from **VersaCross™ RF Wire** insertion into femoral introducer.
 - 14.5 ± 6.6 min for RFA and 19.2 ± 11.7 min for CBA from initial vascular access.




Figure 1. Transseptal puncture time during RF ablation (EAM + ICE) and cryoballoon ablation (ICE) using the **VersaCross™ RF Transseptal Solution** (Baylis Medical).

DISCUSSION & CONCLUSIONS

- ▶ RFA and CBA can be performed safely using the **VersaCross™ RF Transseptal Solution** without the use of fluoroscopy or lead.
- ▶ The **VersaCross™ RF Transseptal Solution** enabled more efficient and faster catheter ablation procedures compared to conventional techniques by:
 - Effective fluoroless visualization using EAM and/or ICE.
 - Reducing the number of device exchanges for LA access.
- ▶ TSP time with fluoroless visualization of the **VersaCross™ RF Wire** are comparable to fluoroscopy-guided TSP using RF wire, suggesting fluoroless visualization does not compromise TSP efficiency.¹

¹Sayah N., et al. Initial clinical experience with VersaCross transseptal system for transcatheter mitral valve repair. *Catheter Cardiovasc Interv.* 2021;97(6): 1230-4. <https://doi.org/10.1002/ccd.29365>.

Boston Scientific is a Global Company. Please note that model numbers, indications, contraindications, warnings and specifications may differ depending on geographic region. Not all information displayed in this brochure may be licensed in accordance with Canadian law. Please contact your Boston Scientific representative for local labeling, product specifications and licensed model numbers.

All trademarks are property of their respective owners. Patents Pending and/or issued. CAUTION: The law restricts this device to sale by or on the order of a physician. Indications, Contraindications, Warnings, and Instructions For Use can be found in the product labelling supplied with each device or at www.baylismedical.com.

Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

**Boston
Scientific**
Advancing science for life™

© 2023 Boston Scientific Corporation or
its affiliates. All rights reserved.

EP-1525115-AA